Balance Sheet
Cash Flow Statement
AmortizationOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Share-based Compensation (2016 - 2022)

Historic Share-based Compensation for RedHill Biopharma (RDHL) over the last 11 years, with Q4 2022 value amounting to $1.1 million.

  • RedHill Biopharma's Share-based Compensation fell 3936.0% to $1.1 million in Q4 2022 from the same period last year, while for Dec 2022 it was $5.7 million, marking a year-over-year decrease of 4442.81%. This contributed to the annual value of $665000.0 for FY2024, which is 5962.36% down from last year.
  • RedHill Biopharma's Share-based Compensation amounted to $1.1 million in Q4 2022, which was down 3936.0% from $1.6 million recorded in Q3 2022.
  • RedHill Biopharma's Share-based Compensation's 5-year high stood at $5.3 million during Q2 2021, with a 5-year trough of $468000.0 in Q3 2018.
  • In the last 5 years, RedHill Biopharma's Share-based Compensation had a median value of $839000.0 in 2018 and averaged $1.3 million.
  • Per our database at Business Quant, RedHill Biopharma's Share-based Compensation soared by 74654.9% in 2021 and then plummeted by 8828.21% in 2022.
  • RedHill Biopharma's Share-based Compensation (Quarter) stood at $671000.0 in 2018, then rose by 11.62% to $749000.0 in 2019, then skyrocketed by 44.46% to $1.1 million in 2020, then soared by 73.29% to $1.9 million in 2021, then tumbled by 39.36% to $1.1 million in 2022.
  • Its last three reported values are $1.1 million in Q4 2022, $1.6 million for Q3 2022, and $618000.0 during Q2 2022.